Autotelic Bio's “ATB-610”, a selective ALK5 inhibitor with inhalation therapy for IPF treatment, was selected to research project by KDDF Autotelic Bio..

Autotelic Bio announced that they had appointed two experts; MD. Yong-Kwan Jun, former director of Development Headquarters at Boryung Biopharma, and Ph. D. Cha..

"Providing cancer patients with innovative new drugs improving significantly quality of life" Autotelic Bio is working on the development of new drug with si..

AutotelicBio & Jeil Pharm signed a joint development and technology transfer agreement for ATB-101 (Hypertension/Diabetes Incrementally modified drug)...

Autotelic Bio, a bio startup, located in Chungcheongbuk-do has R & D funding of 500 million matching achievements by selecting a TIPS task